Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II clinical trial evaluating GMA131

Next Previous
X
Search
Trial Profile

A phase I/II clinical trial evaluating GMA131

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GMA 131 (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Nov 2022 According to Gmax Biopharm media release, company application of investigation of New Drug (IND) for GMA131 injection was approved by the US FDA on Nov 11, 2022 for clinical study on diabetic kidney disease (DKD)
    • 26 Nov 2021 New trial record
    • 11 Nov 2021 According to Gmax Biopharm media release, company planned to submit IND application for initiation of phase I/II trials in the US and China.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top